Development of Lyophilised Eudragit(®) Retard Nanoparticles for the Sustained Release of Clozapine via Intranasal Administration

Clozapine (CZP) is the only effective drug in schizophrenia resistant to typical antipsychotics. However, existing dosage forms (oral or orodispersible tablets, suspensions or intramuscular injection) show challenging limitations. After oral administration, CZP has low bioavailability due to a large...

Descripción completa

Detalles Bibliográficos
Autores principales: Lombardo, Rosamaria, Ruponen, Marika, Rautio, Jarkko, Ghelardini, Carla, Di Cesare Mannelli, Lorenzo, Calosi, Laura, Bani, Daniele, Lampinen, Riikka, Kanninen, Katja M., Koivisto, Anne M., Penttilä, Elina, Löppönen, Heikki, Pignatello, Rosario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224374/
https://www.ncbi.nlm.nih.gov/pubmed/37242796
http://dx.doi.org/10.3390/pharmaceutics15051554

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224374/
https://www.ncbi.nlm.nih.gov/pubmed/37242796
http://dx.doi.org/10.3390/pharmaceutics15051554

Ejemplares similares